Sellas Life Sciences (SLS) reported a Q2 loss late Tuesday of $0.05 per diluted share, narrowing from a loss of $0.07 a year earlier.

Two analysts polled by FactSet expected a loss of $0.05.

As of June 30, the company had cash and cash equivalents of about $138.3 million.